Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of the SYCAMORE trial, a 12-month Phase 2 randomized double-blind, placebo-controlled, safety, tolerability and exploratory efficacy study for REC-994 in symptomatic CCM patients.

REC-994 met its primary endpoint of safety and tolerability, demonstrating a similar profile across placebo and both 200mg and 400mg dosage-arms with regard to the frequency and severity of adverse events after 12 months of treatment. Magnetic resonance imaging-based secondary efficacy endpoints showed a trend towards reduced lesion volume and hemosiderin ring size in patients at the highest dose (400mg) as compared to placebo. Time-dependent improvement in these trends at the 400mg dose was also observed in this signal-finding study. Improvements in either patient or physician-reported outcomes were not yet seen at the 12 month time point. A meeting with the FDA is anticipated as soon as practical to discuss plans for an additional clinical study. Recursion plans to present data from this trial at a forthcoming medical conference and intends to submit these data for publication in a peer reviewed scientific journal.

'These studies are making significant strides in the development of therapeutics for CCM. The data from this readout is an impressive start and will provide a valuable contribution to the existing CCM literature and strongly supports the need for a future study, with a longer duration and a larger patient cohort,” said Dr. Jan-Karl Burkhardt, MD, Division Head, Cerebrovascular Surgery, University of Pennsylvania and Principal Investigator of the study. Connie Lee, Psy.D., founder and CEO of the Alliance to Cure Cavernous Malformation added: “I speak for the patients who have participated in the trial and those who have been cheering from the sidelines while waiting for news. This promising start is a critical step forward and will bring hope to thousands of families who currently have no options but brain or spinal cord surgery. The Alliance to Cure Cavernous Malformation looks forward to partnering with Recursion as they move to the next stage of the REC-994 program.”

“We are encouraged by the recent data from our signal-finding Phase 2 study in CCM, where the trial successfully met its primary safety endpoint and became the first investigational therapy to demonstrate safety alongside some promising trends in exploratory efficacy endpoints. These results provide critical insights that will inform our next study design, including exploring study duration, higher doses, and a larger cohort of patients,' said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer of Recursion. 'This is the first of several key clinical readouts for the company and represents an early proof-of-platform milestone for our constantly evolving Recursion OS, as we build upon our success in drug discovery with expertise and execution in mid-phase development. We are deeply grateful to the patients and investigators, and we are committed to advancing potential transformational therapies for CCM and beyond.”

Background on Cerebral Cavernous Malformation (CCM)

CCM is a neurovascular condition that impacts approximately 360,000 symptomatic individuals in the US and EU5. The disease is often underdiagnosed and potentially affects over 1 million patients worldwide. CCM manifests as vascular malformations of the spinal cord and brain characterized by abnormally enlarged capillary cavities without intervening brain parenchyma. Patients with CCM lesions are at substantial risk for seizures, headaches, progressive neurological deficits, and potentially fatal hemorrhagic stroke. Currently, only non-pharmacologic treatments including microsurgical resection and stereotactic radiosurgery are available options for this high unmet need patient population. However, surgical resection or stereotactic radiosurgery is not always feasible because of location and may not be curative.

About REC-994

REC-994 is an orally bioavailable, superoxide scavenger small molecule under development for the treatment of symptomatic CCM. The potential of REC-994 in CCM was demonstrated using the earliest version of what would become the foundational technology underlying the Recursion OS. Subsequently, REC-994 demonstrated preclinical activity in models for CCM and tolerability and suitability for chronic dosing in Phase 1 single ascending dose escalation (SAD) and multiple ascending dose escalation (MAD) trials in healthy volunteers directed and executed by Recursion. Recursion has sought and received Orphan Drug Designation for REC-994 in symptomatic CCM in the US and Europe.

About the Trial

Our Phase 2 SYCAMORE clinical trial is a randomized, double-blind, placebo-controlled study of two doses of REC-994 in participants with CCM. The primary endpoint of the study is safety and tolerability. Secondary efficacy endpoints include MRI-based endpoints, clinician and patient reported outcomes, as well as selected biomarkers. This trial was fully enrolled in June 2023 with 62 participants, and 80% of participants who completed 12 months of treatment have entered the long-term extension study. This signal-finding study was not powered to demonstrate statistical significance.

About Recursion

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, London, and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media Contact
Media@Recursion.com

Investor Contact
Investor@Recursion.com

Forward-Looking Statements

This document contains information that includes or is based upon 'forward-looking statements' within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding Recursion’s anticipated meeting with the FDA; Recursion’s plans to present SYCAMORE trial data at a medical conference and submit the data for publication; the clinical relevance of the SYCAMORE trial data and obtaining additional confirmatory data; promising trends in REC-994 efficacy endpoints; advancing potential transformational therapies for CCM and beyond; subsequent REC-994 studies and their results and advancing Recursion’s REC-994 program further; the size of the potential CCM patient population; Recursion OS and other technologies potential and advancement of the future of medicine; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, our subsequent Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.


Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability

THỦ THUẬT HAY

9 tính năng phải thuộc lòng khi sử dụng iPhone/iPad

iPhone/iPad là những sản phẩm thông minh với nhiều tính năng hấp dẫn đến từ Apple, và hôm nay mình sẽ liệt kê ra 13 tính năng trên iPhone/iPad hấp dẫn nhất phải biết khi sử dụng các thiết bị này. Cùng tìm hiểu xem, lâu

Thay đổi giọng nói trong cuộc gọi vui vẻ hơn với VoiceChanger X

Bất ngờ khi trong tuần này, Limneos đã cập nhật và phát hành tweak VoiceChanger X. Bây giờ, bạn có thể sống lại cùng một tweak vui nhộn mà bạn có thể đã trải nghiệm trong năm 2013 trên tất cả các máy chạy iOS 11 và đã

Todobook: Công cụ giới hạn thời gian truy cập cho các dịch vụ mạng xã hội

Tính năng chính của Todobook là giới hạn thời gian truy cập cho các dịch vụ mạng xã hội phổ biến như Facebook hay Youtube. Sau đó công cụ này sẽ hiển thị lời nhắc do người dùng ngay trên giao diện trình duyệt.

Kích hoạt thanh điều hướng ánh sáng trên Windows 10 Mobile

Trên Windows 10 Mobile chúng ta có một thanh kéo chỉnh độ sáng màn hình nhưng vì lý do gì đó mà một số dòng cũ lại không xuất hiện. Thật may mắn là chúng ta có thể đem thanh kéo này lên mọi dòng máy bằng cách tùy chỉnh

Samsung Max: Ứng dụng giúp tiết kiệm dữ liệu cho smartphone Galaxy

Là ứng dụng dành riêng cho smartphone Galaxy, Samsung Max sẽ có hai chế độ chính bao gồm 'Tiết Kiệm Dữ Liệu' và 'Bảo Vệ Quyền Riêng Tư'. Trong đó, chế độ tiết kiệm dữ liệu sẽ nén trang web và các dữ liệu media mà người

ĐÁNH GIÁ NHANH

Đánh giá ASUS ROG Strix XG27VQ: Thiết kế hầm hố, màu sắc đẹp, giá 12 triệu

Thiết kế của ROG Strix XG27VQ vẫn rất ngầu theo ngôn ngữ Mayan được ASUS áp dụng trên sản phẩm của mình từ cách đây 2 năm. Vỏ được làm bằng nhựa sần, màu xám tro đậm hơn so với các phiên bản màn hình dòng ROG trước đây

Đánh giá smartwatch DT No.1 F3: phong cách thể thao, chống nước, pin 1 năm

DT No.1 F3 là chiếc smartwatch mang phong cách trẻ trung, hiện đại, thời gian sử dụng lên đến 1 năm. Ngoài ra, chiếc smartwatch này còn có khả năng chống nước. So với phiên bản F2, DT No.1 F3 lần này có thiết kế thể

Đánh giá Honor 7A: Quá nhiều yếu tố hấp dẫn với giá 2,89 triệu đồng

Màn hình 18:9 dẫn đầu xu hướng smartphone 2018 với nhiều ưu điểm như hiển thị được nhiều thông tin khi lướt web hơn, những bộ phim tỷ lệ 21:9 hiển thị tốt hơn so với 16:9 trước đây. Đặc biệt là khi làm màn hình dài hơn